-
-
-
-
-
-
-
FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)
-
-
48,739 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All